| | | 重庆正川医药包装材料股份有限公司 第五届董事会第二次会议决议公告 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）及指定信 息披露媒体上披露的《重庆正川医药包装材料股份有限公司 2025 年第三季度报 告》。 特此公告。 重庆正川医药包装材料股份有限公司董事会 本次会议由董事长邓勇先生召集和主持，公司高级管理人员及相关人员列席 了会议。本次会议的召集、召开和表决程序均符合《公司法》等法律、行政法规 以及《公司章程》《公司董事会议事规则》的有关规定，会议的召集、召开合法 有效。 二、董事会会议审议情况 会议审议通过了《关于公司 2025 年第三季度报告的议案》 公司 2025 年第三季度报告的编制程序符合法律、法规、《公司章程》和公司 管理制度的各项规定；本次季度报告的内容真实、准确、完整，不存在任何虚假 记载、误导性陈述或者重大遗漏，报告客观地反映了公司 2025 年第三季度的财 务及经营状况。 表决结果：9 票同意、0 票反对、0 票弃权。 本议案已经公司第五届董事会审计委员会第二次会议审议通过。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重 ...

Group 1 - The core viewpoint of the news is that Zhengchuan Co., Ltd. reported a significant decline in its third-quarter performance for 2025, with revenue and net profit both decreasing substantially compared to the previous year [1] Group 2 - Zhengchuan Co., Ltd. reported approximately 458 million yuan in revenue for the first three quarters of 2025, representing a year-on-year decrease of 24.92% [1] - The net profit attributable to shareholders of the listed company was approximately 16.34 million yuan, a year-on-year decrease of 68.54% [1] - The basic earnings per share were 0.11 yuan, down 67.65% year-on-year [1] Group 3 - As of the report, Zhengchuan Co., Ltd. has a market capitalization of 3 billion yuan [2]

Group 1 - The core point of the article is that Zhengchuan Co., Ltd. announced the convening of its fifth board meeting to review the third quarter report for 2025 [1] - For the year 2024, the revenue composition of Zhengchuan Co., Ltd. indicates that the pharmaceutical manufacturing sector accounts for 99.58% of total revenue, while other businesses contribute 0.42% [1] - As of the report, Zhengchuan Co., Ltd. has a market capitalization of 3 billion yuan [1] Group 2 - The article highlights that Chinese innovative drugs have generated $80 billion in overseas licensing deals this year [1] - It features an interview with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine and the cooling fundraising environment in the primary market [1]

Financial Performance - The company's operating revenue for the third quarter was ¥134,081,892.26, a decrease of 9.98% compared to the same period last year[4] - The total profit for the quarter was ¥1,546,641.29, reflecting a significant decline of 80.83% year-over-year[4] - The net profit attributable to shareholders was ¥2,251,002.92, down 70.23% from the previous year[4] - The net profit after deducting non-recurring gains and losses for the quarter was -¥55,800.75, a decrease of 100.77% compared to the same period last year[4] - The basic earnings per share for the quarter was ¥0.02, a decline of 60.00% year-over-year[5] - The company experienced a 70.85% decrease in total profit for the year-to-date period, totaling ¥17,029,719.73[4] - Total operating revenue for the first three quarters of 2025 was RMB 457.75 million, a decrease of 25% compared to RMB 609.66 million in the same period of 2024[17] - Net profit for the first three quarters of 2025 was RMB 16.34 million, a decline of 68.6% compared to RMB 51.94 million in 2024[18] - Operating profit for the first three quarters of 2025 was RMB 17.07 million, a decrease of 72% from RMB 60.86 million in 2024[17] - Basic earnings per share for the first three quarters of 2025 were RMB 0.11, compared to RMB 0.34 in the same period of 2024[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,891,506,649.32, a decrease of 3.34% from the end of the previous year[5] - As of September 30, 2025, the company's total assets amounted to RMB 1,891,506,649.32, a decrease from RMB 1,956,811,650.01 as of December 31, 2024[13] - The company's total liabilities decreased to RMB 688,884,142.36 from RMB 733,404,723.33, reflecting a decline of approximately 6.1%[15] - Total current liabilities decreased to RMB 221,494,277.82 from RMB 270,080,438.76, a reduction of about 18%[15] - The equity attributable to shareholders decreased to RMB 1,202,622,506.96 from RMB 1,223,406,926.68, a decrease of about 1.7%[15] - The non-current assets totaled RMB 1,014,587,035.51, down from RMB 1,080,952,079.64, indicating a decrease of about 6.1%[14] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥105,822,452.35, an increase of 20.92%[4] - Cash flow from operating activities for the first three quarters of 2025 was RMB 105.82 million, an increase of 20.9% compared to RMB 87.52 million in 2024[20] - Cash flow from investing activities for the first three quarters of 2025 was negative RMB 16.82 million, a significant decline from positive RMB 147.35 million in 2024[21] - Cash and cash equivalents at the end of the first three quarters of 2025 totaled RMB 120.65 million, down from RMB 311.24 million at the end of 2024[21] - The company's cash and cash equivalents increased to RMB 140,079,429.34 from RMB 108,902,577.00, reflecting a growth of approximately 28.5%[13] Inventory and Receivables - Accounts receivable rose to RMB 163,535,744.01, up from RMB 148,208,950.23, indicating an increase of about 10.3%[13] - Inventory levels increased to RMB 258,864,827.79 from RMB 250,483,335.27, representing a growth of approximately 3.4%[13] - The company reported a significant increase in prepayments, which rose to RMB 8,118,126.14 from RMB 2,509,823.19, marking an increase of approximately 224%[13] Market Conditions - The company attributed the decline in profits to intensified competition in the pharmaceutical market and fluctuations in downstream customer demand[8] Tax and Other Expenses - The company reported a tax expense of RMB 690,422.36 for the first three quarters of 2025, a significant decrease from RMB 6.47 million in 2024[18] - The company did not report any net profit from subsidiaries under common control for the periods in question[19] - The company has no significant changes in the shareholding structure or related party transactions during the reporting period[12]

Core Insights - The company reported a third-quarter revenue of 134 million, representing a year-on-year decline of 9.98% [1] - The net profit for the third quarter was 2.251 million, showing a significant year-on-year decrease of 70.23% [1] - For the first three quarters, the total revenue amounted to 458 million, which is a year-on-year decrease of 24.92% [1] - The net profit for the first three quarters was 16.3393 million, reflecting a year-on-year decline of 68.54% [1]

Core Viewpoint - Chongqing Zhengchuan Pharmaceutical Packaging Materials Co., Ltd. has elected a new employee representative director and made significant decisions regarding its board of directors and convertible bond price adjustments [1][4][29]. Group 1: Election of Employee Representative Director - The company held an employee representative meeting on October 14, 2025, where Mr. Chen Jiyang was elected as the employee representative director for the fifth board of directors [1]. - The new board consists of nine members, including the employee representative director, which complies with legal and regulatory requirements [1][4]. Group 2: Board of Directors Meeting - The first meeting of the fifth board of directors was held on October 14, 2025, with all nine directors present [5][6]. - The meeting approved the exemption of notification period requirements for the meeting, allowing for timely progress on board-related matters [7]. Group 3: Convertible Bond Price Adjustment - The board proposed a downward adjustment of the "Zhengchuan Convertible Bond" conversion price due to the stock price falling below 90% of the conversion price for at least 15 trading days [9][39]. - The conversion price was adjusted from 45.77 yuan per share to 20.07 yuan per share, effective from October 16, 2025 [10][34]. - The bond will be suspended from conversion on October 15, 2025, and will resume conversion on October 16, 2025 [30][42]. Group 4: Board of Directors Composition and Appointments - The fifth board of directors includes five non-independent directors, three independent directors, and one employee representative director, with a term of three years [45][48]. - Mr. Deng Yong was elected as the chairman of the board, and Mr. Deng Qiuhan was appointed as the general manager [12][15]. - Other key appointments include vice general managers, a financial officer, a board secretary, and a securities representative, all with a term of three years [18][21][24].

Core Viewpoint - Zhengchuan Co., Ltd. announced the election of Mr. Deng Yong as the chairman of the board on the evening of October 14 [2] Company Summary - Zhengchuan Co., Ltd. has made a significant leadership change by electing a new chairman [2]

Core Points - Zhengchuan Co., Ltd. announced the election of Mr. Chen Jiyang as the employee representative director of the fifth board of directors [1] Group 1 - The company has made a significant governance change by electing a new employee representative director [1]

重庆源伟律师事务所 关于重庆正川医药包装材料股份有限公司 2025 年第一次临时股东大会的法律意见书 致：重庆正川医药包装材料股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共 和国证券法》、中国证券监督管理委员会发布的《上市公司股东会规则》（以下 简称"《股东会规则》"）和《上海证券交易所上市公司自律监管指引第 1 号-- 规范运作》等法律、行政法规、规范性文件以及《重庆正川医药包装材料股份 有限公司章程》（以下简称"《公司章程》"）的规定，重庆源伟律师事务所(以 下简称"本所")接受重庆正川医药包装材料股份有限公司（以下简称"公司") 的委托，指派程源伟、岳迪律师出席公司于 2025 年 10 月 14 日 14 点 30 分在重 庆市北碚区京东方大道 357 号正川永成研发楼三楼会议室召开的 2025 年第一次 临时股东大会(以下简称"本次股东大会")，对本次股东大会的召集、召开程 序的合法性、召集人和出席会议人员资格的合法有效性、会议表决程序和表决 结果的合法有效性出具法律意见书。 为出具本法律意见书，本所律师对本次股东大会所涉及的有关事项进行了审 查，查阅了本所律师认 ...

证券代码：603976 证券简称：正川股份 公告编号：2025-065 重庆正川医药包装材料股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次股东大会由公司董事会召集，董事长邓勇先生主持，会议采用现场投票 与网络投票相结合的方式进行表决，会议的召集、召开及表决方式符合《公司法》 及《公司章程》的规定。 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 1、出席会议的股东和代理人人数 166 2、出席会议的股东所持有表决权的股份总数（股） 102,229,090 3、出席会议的股东所持有表决权股份数占公司有表决权股 份总数的比例（%） 67.6101 (一) 股东大会召开的时间：2025 年 10 月 14 日 (二) 股东大会召开的地点：重庆市北碚区京东方大道 357 号正川永成研发楼 三楼会议室 (五) 公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席9人； 2、公司在任监事3人，出席3人； 3、董事会秘书费世平先生出 ...